# Randomized Sitagliptin Withdrawal Study (MK-0431-845)

> **NCT02738879** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 746 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Placebo to sitagliptin
- **DRUG:** Metformin
- **DRUG:** Metformin XR
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT02738879
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2018-01-22
- **Final completion:** 2018-01-30
- **Target enrollment:** 746 (ACTUAL)
- **Last updated:** 2019-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738879, "Randomized Sitagliptin Withdrawal Study (MK-0431-845)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02738879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*